Full-Time

Accelerator Software Engineering

Confirmed live in the last 24 hours

Deadline 10/17/25
Sanofi

Sanofi

10,001+ employees

Develops pharmaceuticals and vaccines globally

No salary listed

Mid, Senior

Marcy-l'Étoile, France

Hybrid

60% office based, 40% remote

Category
Backend Engineering
Full-Stack Engineering
Software Engineering
Required Skills
Agile
Requirements
  • Fluent in English and French
  • Excellent communication and presenting skills, including with executive stakeholders
  • Track-record of problem-solving and overcoming roadblocks in a complex environment
  • MS in software engineering or computer science or equivalent
Responsibilities
  • Technical and people leadership and guidance for engineering and agile teams
  • Developing high performance, highly available & scalable applications with a micro-services architecture and an understanding of observability
  • Add to our existing services or roll out new services to support the needs
  • Participate in defining new product requirements and design together with the product team
  • Built the team from the ground up, in collaboration with the other Accelerators. Create a space that people love to work in
  • Be a driving part of the M&S Accelerator leadership team
  • You build it, you run it
  • You’re not expected to write code, but be very close to it and be able to provide guidance to the teams
Desired Qualifications
  • Experience in leading and managing high-performing teams in a fast-paced, technology-driven environment, preferably within manufacturing or product development
  • Evaluating performance, providing objectives and actionable feedback
  • Scaling systems sustainably through mechanisms like automation, and evolving systems by influencing changes that improve reliability and velocity
  • Practice in performing sustainable incident response and blameless postmortems
  • Willingness to learn new technologies and strategies

Sanofi provides healthcare solutions through its pharmaceutical and biotechnology products, focusing on treatments and vaccines for various medical needs. The company conducts extensive research and development to create new therapies and improve existing ones, particularly in areas like immunology, oncology, and rare diseases. Sanofi's products include prescription medicines, over-the-counter items, and vaccines, which are distributed to patients, healthcare professionals, and governments. What sets Sanofi apart from its competitors is its strong emphasis on scientific innovation and strategic partnerships, allowing it to maintain a diverse product pipeline. The company's goal is to enhance health outcomes and improve the quality of life for people globally.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Simplify Jobs

Simplify's Take

What believers are saying

  • Sanofi's acquisition of Blueprint Medicines expands its rare immunological disease portfolio.
  • The FDA approval of Dupixent addresses a large unmet need in dermatology.
  • Sanofi's 20% profit growth in Q1 2025 highlights effective market strategies.

What critics are saying

  • Increased competition in immunology could impact Sanofi's market share.
  • Potential delays in regulatory approvals may affect new product launches.
  • Integration challenges from acquisitions could disrupt operations and delay synergies.

What makes Sanofi unique

  • Sanofi's R&D focuses on unmet needs in immunology, oncology, and rare diseases.
  • The company leverages strategic partnerships to enhance its innovative treatment pipeline.
  • Sanofi's global reach allows it to navigate diverse regulatory environments effectively.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Professional Development Budget

Parental Leave

Company News

Investors Hangout
Jul 1st, 2025
Adagene Secures $25M Investment from Sanofi

Adagene Inc. has secured a strategic investment of up to $25 million from Sanofi to advance its research and development, particularly for the clinical trials of muzastotug (ADG126), an anti-CTLA-4 SAFEbody targeting microsatellite stable colorectal cancer. This funding will extend Adagene's operational runway into 2027 and includes a phase 2 trial with over 100 patients. The partnership also allows Sanofi a role in Adagene's Scientific Advisory Board.

Sanofi
Jun 18th, 2025
Press release: Sanofi successfully prices €1.5 billion bond issue

Sanofi successfully prices €1.5 billion bond issue Paris, June 17, 2025 - Sanofi announces that it has successfully priced its offering of €1.5 billion of notes across 2 tranches:  €750...

PharmiWeb
Jun 3rd, 2025
Asco: New Sarclisa Data Support Subcutaneous Administration With On-Body Injector

New data from two clinical studies demonstrated that Sarclisa administered subcutaneously via an investigational on-body injector shortened treatment time to minutes with similar efficacy and safety compared to intravenous infusionStudies used Enable Injections’ enFuse ® on-body injector, an automated hands-free injectoron-body injector, an automated hands-free injector Data will form the basis of global regulatory submissions across all currently approved lines of treatmentParis, June 3, 2025. New data from two clinical studies of the investigational use of Sarclisa administered subcutaneously (SC) via an on-body injector (OBI) (also referred to as an on-body delivery system) in relapsed or refractory multiple myeloma (R/R MM) support the potential use of this innovative delivery method to advance patient care, while upholding Sarclisa’s efficacy and safety profile. The results were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting and include full data from the IRAKLIA phase 3 study, the first to incorporate the use of an OBI in the treatment of MM, and demonstrate non-inferior efficacy and pharmacokinetics compared to Sarclisa intravenous (IV) infusion.Alyssa Johnsen, MD, PhDGlobal Therapeutic Area Head, Immunology and Oncology Development“Our subcutaneous clinical program is rooted in our mission to address patient needs and reduce treatment burden in multiple myeloma. We believe the novel on-body injector represents a significant innovation that could improve and streamline the treatment process for both patients and providers. We are pleased to share these data, the first to evaluate an on-body injector with a multiple myeloma treatment, and look forward to potentially bringing this formulation and administration option to the multiple myeloma community.”The OBI offers the potential to improve the overall patient experience in MM treatment. Recent studies and surveys suggest the use of an OBI may be associated with greater convenience, flexibility, and patient satisfaction compared to IV or manual SC administration methods.1 In addition, an OBI may also streamline the administration process for providers, potentially reducing the physical burden on nurses and enabling them to possibly move freely through the use of a hands-free device while monitoring the patient during injection.The IRAKLIA phase 3 study and the IZALCO phase 2 study presented at ASCO were conducted using Enable Injections’ enFuse® hands-free OBI, an automated injector designed to subcutaneously administer high-volume medicines beginning with the click of a button, to administer the hyaluronidase-free SC formulation of Sarclisa

GlobeNewswire
Jun 2nd, 2025
Press Release: Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology

Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology Adds fast-growing...

Sanofi
May 23rd, 2025
Press Release: Sanofi to acquire Vigil Neuroscience, Inc., adding a new investigational medicine to treat Alzheimer’s disease to the neurology pipeline

Sanofi to acquire Vigil Neuroscience, Inc., adding a new investigational medicine to treat Alzheimer’s disease to the neurology pipeline Paris, May 22, 2025. Sanofi announced today that it has...